Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus reported a remarkable 235% year-over-year increase in net revenue, reaching $26.1 million for Q2 2021, significantly exceeding its annualized revenue run rate goal of $100 million.
The company ended the quarter with a strong cash position of $131.7 million and is on track for a European launch in early 2022, targeting a potential $470 million market. Key drivers included increased Jeuveau® sales and a growing customer base, with over 6,000 purchasing accounts and 200,000 registered in its loyalty program.
Evolus, a performance beauty company, will announce its second quarter 2021 financial results on August 4, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, including a Q&A session. Interested participants can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international) and via their Investor Relations webpage. Evolus is known for its FDA-approved aesthetic neurotoxin, Jeuveau®, which aims to transform the beauty market. For more information, visit www.evolus.com.
Evolus, Inc. (Nasdaq: EOLS) has appointed David K. Erickson as Vice President of Investor Relations, effective immediately. With over 25 years of experience in investor relations and the healthcare sector, Erickson is expected to enhance the company's strategic investor communications. His prior roles include positions at Establishment Labs Holdings and Edwards Lifesciences. Evolus aims to expand its global presence, including a European launch anticipated in early 2022, which will further benefit from Erickson's industry connections and expertise.
Evolus, Inc. (Nasdaq: EOLS) announced a peer-reviewed article in Dermatologic Surgery highlighting prabotulinumtoxinA (Jeuveau®)'s efficacy for treating glabellar lines in patients with Skin of Color (SOC). The study compared outcomes in 492 patients and found responder rates were slightly lower for SOC patients. Notably, the headache was the most common adverse event, affecting 12.1% of SOC patients. With growing demand from SOC patients, understanding the effectiveness and safety differences between SOC and non-SOC populations becomes crucial for dermatologists.
Evolus, Inc. (Nasdaq: EOLS) has appointed Dan Stewart as Vice President and General Manager of its International business. With over 20 years of experience in medical aesthetics, Stewart is expected to lead Evolus' global expansion, beginning with the European launch of Nuceiva™ in early 2022. The Chief Marketing Officer praised Stewart's successful track record. Evolus is known for its customer-centric approach and innovative products, including Jeuveau®, a unique neurotoxin approved for aesthetics.
Evolus, Inc. (Nasdaq: EOLS) reported Q1 2021 net revenues of $12.2 million, a 16% increase from the previous year, aided by the resolution of an International Trade Commission (ITC) case. The company's pro forma cash position stood at $140 million as of March 31, 2021. The U.S. Jeuveau® business is on track for a $100 million annual revenue run rate in Q2 2021. Moreover, operating expenses decreased by 25.7% year-over-year, while gross margins are expected to stabilize post-September 2022.
Evolus, a performance beauty company, announced two Phase II peer-reviewed studies published in Aesthetic Surgery Journal showcasing the safety and efficacy of repeat doses of Jeuveau® for treating glabellar lines. Conducted to support regulatory approval in North America and Europe, the studies indicate prolonged use is safe, with decreasing adverse events noted over time. Jeuveau® employs patented Hi-Pure™ technology that minimizes antibody formation. The studies confirm the effectiveness of Jeuveau® as a viable neurotoxin alternative for consumers.
Evolus, a performance beauty company, will report its first quarter 2021 financial results on May 12, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, providing a business update and a Q&A session. Domestic callers can access the call at (866) 916-2317, while international callers should use (703) 925-2662, with conference ID 7749489. A replay will be available until May 19, 2021. The event can also be streamed live via the Evolus Investor Relations website.
Evolus, a performance beauty company, will participate in the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, from 3:30 PM to 4:10 PM ET. The event will feature a fireside chat and 1x1 meetings, allowing investors to engage with management. An audio webcast of the discussion will be accessible on the company's investor relations page and available for replay for 90 days post-event. Evolus is known for its aesthetic neurotoxin, Jeuveau®, approved by the FDA in 2019, and aims to transform the aesthetic market.
Evolus announced the pricing of a public offering of 9,000,000 shares of common stock at $9.50 each, aiming for gross proceeds of $85.5 million. The offering, expected to close around April 26, 2021, includes an option for underwriters to purchase an additional 1,350,000 shares. Proceeds will fund Jeuveau® growth in the U.S., European pre-launch activities, and general corporate purposes. The offering is managed by SVB Leerink, Stifel, and Cantor, with details available in the prospectus filed with the SEC.